Identification

Name
Cyclopentolate
Accession Number
DB00979  (APRD00893)
Type
Small Molecule
Groups
Approved
Description

A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia. [PubChem]

Structure
Thumb
Synonyms
  • (+-)-Cyclopentolate
  • (±)-cyclopentolate
  • 1-Hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester
  • 2-(dimethylamino)Ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate
  • 2-(dimethylamino)Ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
  • 2-Phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester
  • alpha-(1-Hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester
  • beta-(dimethylamino)Ethyl (1-hydroxycyclopentyl)phenylacetate
  • beta-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate
  • Ciclopentolato
  • Cyclopentolate
  • Cyclopentolatum
  • α-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester
  • β-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate
Product Ingredients
IngredientUNIICASInChI Key
Cyclopentolate Hydrochloride736I6971TE5870-29-1RHKZVMUBMXGOLL-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclogylSolution / drops1 %OphthalmicNovartis1972-12-31Not applicableCanada
CyclopentolateSolution1 %OphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
CyclopentolateSolution0.5 %OphthalmicEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Dom-cyclopentolate HCl Ophthalmic Solution-1%Solution1 %OphthalmicDominion Pharmacal1995-12-311996-09-09Canada
Minims Cyclopentolate Hydrochloride 0.5%Solution / drops0.5 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Minims Cyclopentolate Hydrochloride 1%Solution / drops1 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Odan-cyclopentolateSolution1 %OphthalmicOdan Laboratories Ltd1984-12-31Not applicableCanada
Odan-cyclopentolateSolution0.5 %OphthalmicOdan Laboratories Ltd1984-12-31Not applicableCanada
PMS-cyclopentolate HCl Oph Solution 1%Liquid1 %OphthalmicPharmascience Inc1992-12-312016-10-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ak-pentolateSolution / drops10 mg/mLOphthalmicRebel Distributors1997-01-13Not applicableUs
CyclogylSolution / drops20 mg/mLOphthalmicAlcon, Inc.1975-10-15Not applicableUs
CyclogylSolution / drops5 mg/mLOphthalmicAlcon, Inc.1975-10-15Not applicableUs
CyclogylSolution / drops10 mg/mLOphthalmicAlcon, Inc.1975-10-15Not applicableUs
CyclopentolateSolution / drops5 mg/mLOphthalmicAkorn2015-12-10Not applicableUs
Cyclopentolate HydrochlorideSolution / drops10 mg/mLOphthalmicRebel Distributors1994-04-29Not applicableUs
Cyclopentolate HydrochlorideSolution20 mg/mLOphthalmicFalcon Pharmaceuticals2002-08-222016-10-13Us
Cyclopentolate HydrochlorideSolution / drops10 mg/mLOphthalmicAkorn1997-01-13Not applicableUs
Cyclopentolate HydrochlorideSolution / drops10 mg/mLOphthalmicPhysicians Total Care, Inc.2013-01-10Not applicableUs
Cyclopentolate HydrochlorideSolution / drops10 mg/mLOphthalmicBauch & Lomb Incorporated1994-04-29Not applicableUs
International/Other Brands
Bell Pentolate / Cylate (Ocusoft) / Mydrilate (Intrapharm) / Ocu-Pentolate / Pentolair
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CyclomydrilCyclopentolate Hydrochloride (2 mg/mL) + Phenylephrine hydrochloride (10 mg/mL)Solution / dropsOphthalmicAlcon, Inc.1958-06-30Not applicableUs
Categories
UNII
I76F4SHP7J
CAS number
512-15-2
Weight
Average: 291.3853
Monoisotopic: 291.183443671
Chemical Formula
C17H25NO3
InChI Key
SKYSRIRYMSLOIN-UHFFFAOYSA-N
InChI
InChI=1S/C17H25NO3/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3
IUPAC Name
2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
SMILES
CN(C)CCOC(=O)C(C1=CC=CC=C1)C1(O)CCCC1

Pharmacology

Indication

Used mainly to produce mydriasis and cycloplegia for diagnostic purposes.

Structured Indications
Pharmacodynamics

Cyclopentolate is an anti-muscarinic in the same class as atropine and scopolamine. Cyclopentolate blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. Cyclopentolate thus induces relaxation of the sphincter of the iris and the ciliary muscles. When applied topically to the eyes, it causes a rapid, intense cycloplegic and mydriatic effect that is maximal in 15 to 60 minutes; recovery usually occurs within 24 hours. The cycloplegic and mydriatic effects are slower in onset and longer in duration in patients who have dark pigmented irises.

Mechanism of action

By blocking muscarinic receptors, cyclopentolate produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia).

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
Absorption

Absorbed following ophthalmic administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral LD50 in the rat is 4000 mg/kg and 960 mg/kg in the mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Cyclopentolate.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Anisotropine Methylbromide.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Cyclopentolate.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Cyclopentolate.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Cyclopentolate.Approved
BezitramideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Cyclopentolate.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Bornaprine.Experimental
Botulinum Toxin Type ACyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BCyclopentolate may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Cyclopentolate.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Cyclopentolate.Approved
CimetropiumCyclopentolate may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Cyclopentolate.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Darifenacin.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with DPDPE.Investigational
DronabinolCyclopentolate may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Edrophonium.Approved
EluxadolineCyclopentolate may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Cyclopentolate.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Gallamine Triethiodide.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glucagon recombinant.Approved
GlycopyrroniumCyclopentolate may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Cyclopentolate.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Cyclopentolate.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hyoscyamine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Cyclopentolate.Approved
IpidacrineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Cyclopentolate.Approved
IsoflurophateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Cyclopentolate.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Ketobemidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methantheline.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Cyclopentolate.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Cyclopentolate.Approved
MianserinMianserin may increase the anticholinergic activities of Cyclopentolate.Approved, Investigational
MinaprineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Morphine.Approved, Investigational
NabiloneCyclopentolate may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Orphenadrine.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxyphenonium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Phenglutarimide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Cyclopentolate.Approved
Potassium ChlorideCyclopentolate may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Cyclopentolate.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Cyclopentolate.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Propiverine.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Cyclopentolate.Approved
QuinidineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Quinidine.Approved
RamosetronCyclopentolate may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Cyclopentolate.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Cyclopentolate.Approved, Investigational
TacrineThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tilidine.Experimental
TiotropiumCyclopentolate may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Cyclopentolate.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Cyclopentolate.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Trimethaphan.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Cyclopentolate.Approved
TrospiumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Trospium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Cyclopentolate.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Vecuronium.Approved
Food Interactions
Not Available

References

Synthesis Reference

Treves, G.R.; US. Patent 2,554,511; May 29,1951; assigned to Schieffelin & Co.

General References
  1. Link [Link]
External Links
Human Metabolome Database
HMDB15114
KEGG Compound
C06932
PubChem Compound
2905
PubChem Substance
46504517
ChemSpider
2802
BindingDB
82375
ChEBI
4024
ChEMBL
CHEMBL1201338
Therapeutic Targets Database
DAP001111
PharmGKB
PA164743019
Drugs.com
Drugs.com Drug Page
Wikipedia
Cyclopentolate
ATC Codes
S01FA54 — Cyclopentolate, combinationsS01FA04 — Cyclopentolate
AHFS Codes
  • 52:24.00 — Mydriatics
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnNot AvailableRefractive Error - Myopia1
4Unknown StatusDiagnosticRefractive Errors1
Not AvailableCompletedScreeningRetinopathy of Prematurity (ROP)1
Not AvailableRecruitingNot AvailableCataracts1

Pharmacoeconomics

Manufacturers
  • Akorn inc
  • Alcon laboratories inc
  • Alcon universal ltd
  • Sola barnes hind
  • Bausch and lomb pharmaceuticals inc
  • Pharmafair inc
Packagers
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic20 mg/mL
Solution / dropsOphthalmic5 mg/mL
Solution / dropsOphthalmic
SolutionOphthalmic10 mg/mL
SolutionOphthalmic20 mg/mL
SolutionOphthalmic5 mg/mL
Solution / dropsOphthalmic10 mg/mL
Solution / dropsOphthalmic0.5 %
Solution / dropsOphthalmic1 %
SolutionOphthalmic0.5 %
SolutionOphthalmic1 %
LiquidOphthalmic1 %
Prices
Unit descriptionCostUnit
Cyclopentolate HCl 1% Solution 15ml Bottle12.99USD bottle
Cyclogyl 2% eye drops11.76USD ml
Cyclopentolate HCl 1% Solution 2ml Bottle9.99USD bottle
Cyclopentolate 1% eye drops9.35USD ml
Cyclogyl 1% eye drops8.97USD ml
Cylate 1% eye drops5.02USD ml
Cyclogyl 0.5% eye drops3.42USD ml
Cyclogyl 1 % Solution0.91USD ml
Ak-pentolate 1% eye drops0.71USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)134-136Treves, G.R.; US. Patent 2,554,511; May 29,1951; assigned to Schieffelin & Co.
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.5 mg/mLALOGPS
logP2.09ALOGPS
logP2.32ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)14.19ChemAxon
pKa (Strongest Basic)8.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity82.81 m3·mol-1ChemAxon
Polarizability32.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9741
Blood Brain Barrier+0.8234
Caco-2 permeable+0.6395
P-glycoprotein substrateSubstrate0.7831
P-glycoprotein inhibitor INon-inhibitor0.6735
P-glycoprotein inhibitor IINon-inhibitor0.9384
Renal organic cation transporterNon-inhibitor0.5874
CYP450 2C9 substrateNon-substrate0.7938
CYP450 2D6 substrateNon-substrate0.7009
CYP450 3A4 substrateSubstrate0.6036
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9413
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9518
Ames testNon AMES toxic0.8284
CarcinogenicityNon-carcinogens0.8492
BiodegradationNot ready biodegradable0.931
Rat acute toxicity2.4300 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9335
hERG inhibition (predictor II)Non-inhibitor0.779
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9000000000-0f0d4362f3985858a9e0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Cyclopentanols / Tertiary alcohols / Trialkylamines / Cyclic alcohols and derivatives / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Monocyclic benzene moiety / Cyclopentanol / Cyclic alcohol / Tertiary alcohol / Amino acid or derivatives / Carboxylic acid ester / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Monocarboxylic acid or derivatives
show 11 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary alcohol, tertiary amino compound, carboxylic ester (CHEBI:4024)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Demayo AP, Reidenberg MM: Grand mal seizure in a child 30 minutes after Cyclogyl (cyclopentolate hydrochloride) and 10% Neo-Synephrine (phenylephrine hydrochloride) eye drops were instilled. Pediatrics. 2004 May;113(5):e499-500. [PubMed:15121994]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34